Q BioMed (Q BioMed) LT-Debt-to-Total-Asset : 0.00 (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Q BioMed's long-term debt to total assests ratio for the quarter that ended in Feb. 2023 was 0.00.

Q BioMed's long-term debt to total assets ratio stayed the same from Feb. 2022 (0.00) to Feb. 2023 (0.00).

Q BioMed LT-Debt-to-Total-Asset Historical Data

The historical data trend for Q BioMed's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed LT-Debt-to-Total-Asset Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.90

0.70

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Q BioMed LT-Debt-to-Total-Asset Calculation

Q BioMed's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2022 is calculated as

LT Debt to Total Assets (A: Nov. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Nov. 2022 )	/	Total Assets (A: Nov. 2022 )
	=	0	/	3.516
	=	0.00

Q BioMed's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2023 is calculated as

LT Debt to Total Assets (Q: Feb. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Feb. 2023 )	/	Total Assets (Q: Feb. 2023 )
	=	0	/	3.465
	=

Q BioMed (OTCPK:QBIO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Q BioMed LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Q BioMed's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1